

8TH ASIAN BIOLOGICS AND BIOSIMILARS CONGRESS

August 10-12, 2017 Beijing, China

Current status in the development of biosimilar market in LATAM region: An update on market barriers, opportunities and regulatory requirements

Edgar Mauricio Rubio
Biopas, USA

Some countries in LATAM are considered between the highest growth emerging markets in pharmaceutical business. Much of the growth of the pharmaceuticals in this region will be around biosimilars. Due to the high concerns of different government policies surrounding health care expenditure and price control and also increasing ageing population, the demand for biologic therapeutics is increasing on. Biosimilars emerge as an option in these countries for affordable medications. Furthermore, the diversity of the region has led to each country to develop own regulatory pathways to approve these products and also encouraging some local industries to develop their own manufacturing and development capabilities in this area. Moreover, this presentation will also discusses the major challenges involved in the business development opportunities of the biosimilar market in LATAM, their current status, barriers and regulatory requirements to develop this market aside of the increasing competition to maintain a stable price model. However, we will also take into consideration some trends that promise the bright future of biosimilars in the LATAM region.

emrubior@gmail.com